Strengthening its foray into immunoassay, Transasia Bio-Medicals Ltd., India’s leading in-vitro diagnostic company, has recently acquired Calbiotech Group of Companies in the US through its German subsidiary Erba Mannheim.
With this new addition, the Transasia-Erba Group is all set to strengthen its foray in ELISA and CLIA assays for human and animal research, including specific assays for autoimmune disorders, cancer and infectious diseases.
“Calbiotech Inc. and Dr Noori Barka have developed an excellent range of immunoassay products that will complement our growing range of diagnostic products. Their expertise in Immunoassay will allow Erba to strengthen our position in this high growth market and integrate their strong R&D programme to further enhance the product development strategy of the Erba Diagnostics Mannheim group,” said Suresh Vazirani, Chairman and Managing Director, Erba Group.
“We are excited to join the growing Erba Mannheim group and enjoy the synergies of being part of a larger organization. We found a strong strategic and cultural fit with Erba Mannheim and are eager to realise the potential of the combined companies,” said Dr Noori Barka, CEO and President of the Calbiotech Group.
“The strength of the Erba brand will support our growing sales activities while enabling Calbiotech to access a wider range of global markets for our products. The acquisition will also bring synergies with Erba’s R&D and work to accelerate the development of our novel and innovative products,” Dr Barka added.
The California-based Calbiotech Group is a global leader in immunoassay development and manufacturing. Whereas, Transasia Bio-Medicals Ltd offers a comprehensive product portfolio spanning all specialties of diagnostics including biochemistry, hematology, immunoassay and blood banking, urinalysis, diabetes, critical care, coagulation, microbiology and molecular diagnostics.
Along with its subsidiaries in Germany, France, Czech Republic, Russia, Turkey, the UK and USA, Transasia now reaches out to millions in over 104 countries.